Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.

Trial Details

NCT ID
NCT04410796
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Osimertinib
  • Carboplatin
  • Pemetrexed
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • San Francisco, California, United States|37.77493,-122.41942
  • Tampa, Florida, United States|27.94752,-82.45843
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Age ≥ 18 years
  • Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution
  • Somatic activating mutation in EGFR in pre-treatment tumor biopsy/ cytology from pleural fluid or cfDNA
  • Either have not started a prior EGFR TKI therapy or may have started osimertinib within 3 weeks of confirming eligibility and enrollment criteria o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →